SCHEMBL4044666

SCHEMBL4044666

O=C(NC1CCCCC1)C(C1CCCCC1)C1(c2ccc(Cl)cc2)Nc2ccc(Br)cc2N1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 2/20 0.42
RAB9A P51151 4/20 0.40
NPC1 O15118 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HPGD P15428 2/20 0.40
KMT2A Q03164 2/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.39
EPHX1 P07099 3/20 0.39
ALDH1A1 P00352 3/20 0.39
CYP2C9 P11712 2/20 0.39
POLB P06746 1/20 0.39
CYP2C19 P33261 1/20 0.39
NR1H4 Q96RI1 3/20 0.38
CYP3A4 P08684 2/20 0.38
KCNH2 Q12809 2/20 0.38
CYP2D6 P10635 1/20 0.38
MAPT P10636 1/20 0.38
ALOX15 P16050 1/20 0.38
HSD11B1 P28845 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4036666 0.92 RAB9A (0.42) RAB9ANPC1SMN1; SMN2HPGDKMT2A
SCHEMBL4036972 0.89 NPC1 (0.41) RAB9ANPC1SMN1; SMN2HPGDEPHX1
SCHEMBL4036796 0.89 NPC1 (0.41) RAB9ANPC1SMN1; SMN2HPGDEPHX1
SCHEMBL4040844 0.87 NR1H4 (0.47) RAB9ANPC1SMN1; SMN2HPGDLMNA
SCHEMBL4035029 0.87 NR1H4 (0.47) RAB9ANPC1SMN1; SMN2HPGDLMNA
SCHEMBL4039101 0.87 NR1H4 (0.44) MDM2RAB9ANPC1SMN1; SMN2HPGD
SCHEMBL4042732 0.87 NR1H4 (0.44) MDM2RAB9ANPC1SMN1; SMN2HPGD
SCHEMBL4045000 0.85 NR1H4 (0.48) RAB9ANPC1SMN1; SMN2KMT2AEPHX1
SCHEMBL4038480 0.85 NR1H4 (0.48) RAB9ANPC1SMN1; SMN2KMT2AEPHX1
SCHEMBL4037444 0.85 NR1H4 (0.48) RAB9ANPC1SMN1; SMN2KMT2AEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP claimed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO claimed
EP-3043865-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2016-07-20 EP disclosed
WO-2015036442-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2015-03-19 WO disclosed
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP disclosed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed